Inotiv (NOTV) to Post Earnings on Wednesday

Inotiv (NASDAQ:NOTV) is expected to announce its Q3 2026 resultson Wednesday, August 5th. Analysts expect Inotiv to post earnings of ($0.47) per share and revenue of $136.6840 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Inotiv (NASDAQ:NOTV) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.30). Inotiv had a negative return on equity of 56.77% and a negative net margin of 17.14%.The firm had revenue of $117.65 million for the quarter, compared to analysts’ expectations of $124.74 million.

Inotiv Stock Performance

NASDAQ NOTV opened at $0.01 on Wednesday. The firm’s 50 day moving average price is $0.08 and its two-hundred day moving average price is $0.26. Inotiv has a twelve month low of $0.08 and a twelve month high of $2.95. The stock has a market cap of $387,256.80, a price-to-earnings ratio of -0.00 and a beta of 3.77.

Institutional Investors Weigh In On Inotiv

Institutional investors have recently made changes to their positions in the company. Balyasny Asset Management L.P. grew its stake in shares of Inotiv by 30.3% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,654,648 shares of the company’s stock valued at $3,011,000 after buying an additional 384,696 shares in the last quarter. Vanguard Group Inc. raised its position in Inotiv by 1.5% during the third quarter. Vanguard Group Inc. now owns 1,404,738 shares of the company’s stock valued at $2,037,000 after acquiring an additional 20,890 shares in the last quarter. Massar Capital Management LP lifted its stake in Inotiv by 133.3% in the second quarter. Massar Capital Management LP now owns 350,000 shares of the company’s stock valued at $637,000 after acquiring an additional 200,000 shares during the last quarter. Citadel Advisors LLC lifted its stake in Inotiv by 99.5% in the third quarter. Citadel Advisors LLC now owns 255,858 shares of the company’s stock valued at $371,000 after acquiring an additional 127,595 shares during the last quarter. Finally, Voleon Capital Management LP bought a new stake in Inotiv in the third quarter worth approximately $205,000. 18.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Inotiv in a report on Friday, April 10th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Inotiv has an average rating of “Hold” and a consensus target price of $1.50.

About Inotiv

Inotiv, Inc, formerly known as Bioanalytical Systems, Inc (NASDAQ: NOTV), is a global contract research organization (CRO) specializing in preclinical drug discovery, development and testing services. The company partners with pharmaceutical, biotech and medical device companies to advance candidate molecules through early‐stage research and safety assessment. Inotiv’s integrated platform spans in vivo and in vitro pharmacology, drug metabolism and pharmacokinetics (DMPK), toxicology, pathology and bioanalysis.

The company’s core service offerings include discovery pharmacology, safety assessment toxicology, pathology, bioanalysis and regulatory support.